Vaccines for children may be available by September and the trials for inoculating those between 2 to 18 years are underway, Priya Abraham, Director of the National Institute of Virology has said.

Covid-19 vaccination for kids is likely to be approved by September, according to two officials privy to the development of the vaccines said. Bharat Biotech’s Managing Director  (MD) Krishna Ella, said the trial phase of the clinical studies in volunteers in the 2-18 age group has been completed.

Priya Abraham added,  “Apart from Zydus Cadila, which will be the first DNA vaccine, another vaccine from Gennova, which is an mRNA vaccine, vaccine candidate of Biological E and Novavax, which will be manufactured by the Serum Institute of India, are in the pipeline”.

According to reports, there are two vaccine candidates that have been tested among children in India: Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCov-D. The Covaxin trial includes 525 volunteers while ZyCov-D’s trials – as part of the phase II/III clinical studies – includes 1,000 volunteers in the 12-18 age group.

ICMR Study: Prevalence of Delta Not Different Between Vaccinated and Unvaccinated

GSK and CureVac’s second Covid vaccine yields stronger immune response

Study suggests regular exercise even in polluted areas may cut mortality risk